Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020–2025)
Year: 2026
Type: article
Abstract: Abnormalities in protein tyrosine kinases (PTKs) are one of the primary drivers of cancer. As a receptor subfamily, fibroblast growth factor receptors (FGFRs) comprise four subtypes-FGFR1 to FGFR4. Their abnormal intracellular expression is a significant cause of tumorigenesis, making FGFRs key therapeutic targets in cancer treatment. This paper primarily summarizes the latest research advances in FGFR inhibitors, aiming to provide insights for future design and synthesis studies of FGFR inhibitors.
Source: International Immunopharmacology
Authors: Rongfei Liu, Jinghui Qi, Yue Liu, Mingyue Hou, Mingyu Zhang, Xuan An, Jinxing Hu
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,220
Award: G8084625364
OpenAlex ID: W7125396197